Close
  Indian J Med Microbiol
 

Figure 2: Elevated expression of TIMELESS and DLX1 associated with metastatic prostate cancer (PCa). ( a ) Elevated TIMELESS expression in metastatic PCa (n = 19) compared to primary PCa (n = 131) and normal prostate tissues (n = 28; microarray gene expression data from the MSKCC Prostate Oncogenome Project). ( b ) Elevated expression of TIMELESS associated with poor patient prognosis. ( c ) Elevated DLX1 expression in both primary and metastatic tumors compared to normal prostate samples (MSKCC cohort). ( d ) Elevated DLX1 expression in five prostate tumors compared to six normal prostate samples. Note that three out of six normal samples have undetectable DLX1 levels. Statistical significance was established using the Student's t-test; *P < 0.05. MSKCC: Memorial Sloan-Kettering Cancer Center.

Figure 2: Elevated expression of <i>TIMELESS</i> and <i>DLX1</i> associated with metastatic prostate cancer (PCa). ( <b>a</b> ) Elevated <i>TIMELESS</i> expression in metastatic PCa (<i>n</i> = 19) compared to primary PCa (<i>n</i> = 131) and normal prostate tissues (<i>n</i> = 28; microarray gene expression data from the MSKCC Prostate Oncogenome Project). ( <b>b</b> ) Elevated expression of <i>TIMELESS</i> associated with poor patient prognosis. ( <b>c</b> ) Elevated <i>DLX1</i> expression in both primary and metastatic tumors compared to normal prostate samples (MSKCC cohort). ( <b>d</b> ) Elevated <i>DLX1</i> expression in five prostate tumors compared to six normal prostate samples. Note that three out of six normal samples have undetectable <i>DLX1</i> levels. Statistical significance was established using the Student's t-test; *<i>P</i> < 0.05. MSKCC: Memorial Sloan-Kettering Cancer Center.